Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What is the role of dose-dense therapy?
van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J. van der Burg ME, et al. Among authors: van doorn hc, van der gaast a. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40. doi: 10.1111/j.1525-1438.2005.00432.x. Int J Gynecol Cancer. 2005. PMID: 16343238 Free article. Review.
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. van der Burg ME, et al. Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096168 Clinical Trial.
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
Aapro MS, van Wijk FH, van der Burg ME, ten Bokkel Huinink W, Vergote I, Guastalla JP, Rosso R, Kobierska A, Beex LV, Namer M, Splinter TE, Vermorken JB. Aapro MS, et al. Among authors: van wijk fh, van der burg me. Eur J Cancer. 2003 May;39(8):1141-3. doi: 10.1016/s0959-8049(03)00198-9. Eur J Cancer. 2003. PMID: 12736114 Clinical Trial.
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group. Green JA, et al. Among authors: van luijk i, van dam p, van diest p, van de vijver m, van der burg me. Eur J Cancer. 2006 Oct;42(15):2539-48. doi: 10.1016/j.ejca.2006.06.015. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16965910 Clinical Trial.
Management of recurrent endometrioid endometrial carcinoma: an overview.
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. van Wijk FH, et al. Among authors: van doorn hc, van der burg me. Int J Gynecol Cancer. 2009 Apr;19(3):314-20. doi: 10.1111/IGC.0b013e3181a7f71e. Int J Gynecol Cancer. 2009. PMID: 19407552 Review.
151 results